Table 1. Open in new tab...

Reference

Study Population

No.

Therapy Duration

Dose, mg, and Frequency

Cmax, μg/mL

AUC_0-24, μg-h/mL

Half-life, h

Allen 1998 [10]

Healthy volunteers

14 d
24 d

150 QD

0.16 ± 0.03
0.21 ± 0.04

1.61 ± 0.43
1.94 ± 0.48

N/A

Benedetti 1990 [11]

Healthy volunteers

1 d
10 d

450 QD
450 QD

0.62
0.61

9.29
5.80

45 ± 6
58 ± 7

Ford 2008 [12]

Healthy volunteers

13 d

300 QD

0.31
(0.27–0.37)

6.11
(5.33–7.01)^a

N/A

Ghannad 2019 [13]

Healthy volunteers

10 d

300 QD

0.54

4.22

N/A

Hamzeh 2003 [14]

Healthy volunteers

14 d

300 QD

0.40 ± 0.14

3.37 ± 0.86

N/A

Kraft 2004 [15]

Healthy volunteers

10
14

10 d
10 d

300 QD
300 QD

0.29
0.29

2.56
2.87

N/A

La Porte 2009 [16]

Healthy volunteers

Single dose

150 once

0.16
(0.06–0.44)

2.22
(0.90–6.03)

41.3
(11.7–84.8)

Narang 1992 [17]

Healthy volunteers

Single dose

150 once, fasted (solution)
150 once, with food (capsule)
150 once, fasted (capsule)

0.24
0.16
0.19

2.71^b
2.41^b
2.27^b

N/A

Polk 2001 [18]

Healthy male volunteers

14 d

300 QD

0.38
(0.30–0.48)

3.39
(2.84–4.03)

N/A

Sekar 2010 [19]

Healthy volunteers

12 d

300 QD

0.57 ± 0.13

4.66 ± 0.97

N/A

van Ingen 2012 [20]

Pulmonary MAC

N/A

4.80 ± 1.46 mg/kg

0.52 ± 0.29

2.28 ± 1.31^c

N/A

Zhang 2011 [21]

Healthy volunteers

11
9

20 d
20 d

150 QD
150 QD

0.19 ± 0.05
0.18 ± 0.06

1.80 ± 0.40
1.80 ± 0.40

N/A

Zhang 2011 [22]

Healthy volunteers

10 d

150 QD

0.19 (30)

1.85 (32)

N/A

Table 1.

Open in new tab

Pharmacokinetics of Rifabutin in Individuals Without HIV

Reference	Study Population	No.	Therapy Duration	Dose, mg, and Frequency	Cmax, μg/mL	AUC_0-24, μg-h/mL	Half-life, h
Allen 1998 [10]	Healthy volunteers	11	14 d 24 d	150 QD	0.16 ± 0.03 0.21 ± 0.04	1.61 ± 0.43 1.94 ± 0.48	N/A
Benedetti 1990 [11]	Healthy volunteers	7	1 d 10 d	450 QD 450 QD	0.62 0.61	9.29 5.80	45 ± 6 58 ± 7
Ford 2008 [12]	Healthy volunteers	15	13 d	300 QD	0.31 (0.27–0.37)	6.11 (5.33–7.01)^a	N/A
Ghannad 2019 [13]	Healthy volunteers	14	10 d	300 QD	0.54	4.22	N/A
Hamzeh 2003 [14]	Healthy volunteers	17	14 d	300 QD	0.40 ± 0.14	3.37 ± 0.86	N/A
Kraft 2004 [15]	Healthy volunteers	10 14	10 d 10 d	300 QD 300 QD	0.29 0.29	2.56 2.87	N/A
La Porte 2009 [16]	Healthy volunteers	20	Single dose	150 once	0.16 (0.06–0.44)	2.22 (0.90–6.03)	41.3 (11.7–84.8)
Narang 1992 [17]	Healthy volunteers	15	Single dose	150 once, fasted (solution) 150 once, with food (capsule) 150 once, fasted (capsule)	0.24 0.16 0.19	2.71^b 2.41^b 2.27^b	N/A
Polk 2001 [18]	Healthy male volunteers	11	14 d	300 QD	0.38 (0.30–0.48)	3.39 (2.84–4.03)	N/A
Sekar 2010 [19]	Healthy volunteers	15	12 d	300 QD	0.57 ± 0.13	4.66 ± 0.97	N/A
van Ingen 2012 [20]	Pulmonary MAC	51	N/A	4.80 ± 1.46 mg/kg	0.52 ± 0.29	2.28 ± 1.31^c	N/A
Zhang 2011 [21]	Healthy volunteers	11 9	20 d 20 d	150 QD 150 QD	0.19 ± 0.05 0.18 ± 0.06	1.80 ± 0.40 1.80 ± 0.40	N/A
Zhang 2011 [22]	Healthy volunteers	14	10 d	150 QD	0.19 (30)	1.85 (32)	N/A

Reference	Study Population	No.	Therapy Duration	Dose, mg, and Frequency	Cmax, μg/mL	AUC_0-24, μg-h/mL	Half-life, h
Allen 1998 [10]	Healthy volunteers	11	14 d 24 d	150 QD	0.16 ± 0.03 0.21 ± 0.04	1.61 ± 0.43 1.94 ± 0.48	N/A
Benedetti 1990 [11]	Healthy volunteers	7	1 d 10 d	450 QD 450 QD	0.62 0.61	9.29 5.80	45 ± 6 58 ± 7
Ford 2008 [12]	Healthy volunteers	15	13 d	300 QD	0.31 (0.27–0.37)	6.11 (5.33–7.01)^a	N/A
Ghannad 2019 [13]	Healthy volunteers	14	10 d	300 QD	0.54	4.22	N/A
Hamzeh 2003 [14]	Healthy volunteers	17	14 d	300 QD	0.40 ± 0.14	3.37 ± 0.86	N/A
Kraft 2004 [15]	Healthy volunteers	10 14	10 d 10 d	300 QD 300 QD	0.29 0.29	2.56 2.87	N/A
La Porte 2009 [16]	Healthy volunteers	20	Single dose	150 once	0.16 (0.06–0.44)	2.22 (0.90–6.03)	41.3 (11.7–84.8)
Narang 1992 [17]	Healthy volunteers	15	Single dose	150 once, fasted (solution) 150 once, with food (capsule) 150 once, fasted (capsule)	0.24 0.16 0.19	2.71^b 2.41^b 2.27^b	N/A
Polk 2001 [18]	Healthy male volunteers	11	14 d	300 QD	0.38 (0.30–0.48)	3.39 (2.84–4.03)	N/A
Sekar 2010 [19]	Healthy volunteers	15	12 d	300 QD	0.57 ± 0.13	4.66 ± 0.97	N/A
van Ingen 2012 [20]	Pulmonary MAC	51	N/A	4.80 ± 1.46 mg/kg	0.52 ± 0.29	2.28 ± 1.31^c	N/A
Zhang 2011 [21]	Healthy volunteers	11 9	20 d 20 d	150 QD 150 QD	0.19 ± 0.05 0.18 ± 0.06	1.80 ± 0.40 1.80 ± 0.40	N/A
Zhang 2011 [22]	Healthy volunteers	14	10 d	150 QD	0.19 (30)	1.85 (32)	N/A

Abbreviations: AUC, area under the curve; Cmax, maximal concentration; QD, once daily; N/A, not reported in study.

^aAUC_0-48, area under drug-concentration time curve from time of dosing to 48 hours after dosing.

^bAUC_0-168, area under drug-concentration time curve from time of dosing to 168 hours after dosing.

^cAUC_0-6/7, area under drug-concentration time curve from time of dosing to 6 or 7 hours after dosing.

This Feature Is Available To Subscribers Only